Contribute Try STAT+ Today

Tumors shrank in one quarter of patients with advanced lung cancer who received a bespoke cell therapy made by doctors at H. Lee Moffitt Cancer Center in Tampa, Fla. In two patients, the researchers found, lung tumors disappeared completely.

Though the study was small, the results are impressive because the patients had tumors in their lungs that were not responding to Opdivo, one of the checkpoint-inhibitor immunotherapies that are now standard of care. That makes these patients particularly difficult to treat effectively.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.